Suchergebnisse - "Brufsky, Adam"

PubPharm (34)

1

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer

enthalten in: The oncologist | 2023

von Gomez Marti, J. | Nasrazadani, A. | Ding, Y. | +2

2

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: Breast cancer research and treatment | 2022

von O'Shaughnessy, J. | Brufsky, A. | Rugo, H. | +15

3

A plain language summary of the ASCENT study : Sacituzumab Govitecan for metastatic triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2021

von Bardia, A. | Hurvitz, S. | Rugo, H. | +7

CommentOn: N Engl J Med. 2021 Apr 22;384(16):1529-1541. - PMID 33882206

4

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Bardia, A. | Hurvitz, S. | Tolaney, S. | +117

CommentIn: Nat Rev Clin Oncol. 2021 Jun;18(6):322. - PMID 33931767

5

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) : end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2020

von Swain, S. | Miles, D. | Kim, S. | +113

CommentIn: Lancet Oncol. 2020 Apr;21(4):471-472. - PMID 32171427

6

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Modi, S. | Saura, C. | Yamashita, T. | +99

CommentIn: Cancer Discov. 2020 Feb;10(2):167. - PMID 31843763

7

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy : A Multicenter, Randomized, Phase II Study

enthalten in: Clinical breast cancer | 2016

von Yardley, D. | Reeves, J. | Dees, E. | +17

8

Is there room for bevacizumab in metastatic breast cancer?

enthalten in: The Lancet. Oncology | 2016

von Brufsky, A.

CommentOn: Lancet Oncol. 2016 Sep;17 (9):1230-9. - PMID 27501767

9

Length of chemotherapy and use of bevacizumab for breast cancer

enthalten in: The Lancet. Oncology | 2014

von Brufsky, A.

CommentOn: Lancet Oncol. 2014 Nov;15(12):1351-60. - PMID 25273343

10

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

enthalten in: Breast cancer research and treatment | 2014

von Yardley, D. | Kaufman, P. | Brufsky, A. | +6